We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Handheld Injection Platform Facilitates Fluid Delivery

By HospiMedica International staff writers
Posted on 19 Jul 2021
A novel microvolume injector (MVI) expedites injection of any high viscosity fluid that requires precision dosing and control. More...


The Altaviz (Irvine, CA, USA) MVI is a self-powered, hydraulic drive mechanism device that can deliver a full range of fluids, from viscid retinal gene therapies and up to the highest viscosity dermal fillers, through 41g equivalent cannulas. The flexible flow controller provides consistent performance across varying downstream resistances. To ensure both drug and therapy dosing accuracy, the MVI has fully integrated visual and audio dose feedback cues to increase the surgeon's ability to hit the dose target.

The integrated dose tracking system is designed to continuously measure drug quantities with sub-microliter precision, and automatically record injection metrics both on-board and through external endpoints (such as a tablet, laptop, or personal computer). Repeatable, precise delivery rates are constantly maintained, even with single handed operation. The MVI Platform also boasts embedded wireless connectivity through Bluetooth for real-time logging and application control.

“Subretinal delivery of extremely high value gene therapies is one of the most promising and demanding surgical procedures done today,” said Jack Auld, CEO of Altaviz. “The problem is that prior to MVI, there were no methods or devices to enable this critical treatment. But we've provided a platform that could solve that. We took a full-system approach to optimize every detail of the procedure…and, we've now optimized it as a platform that can be adapted to other uses as well.”

The availability and usage of high viscosity drugs is growing, often driven by the development of formulations that are highly viscid in nature (100–1000 cP). Such drugs can present non-Newtonian clogging characteristics, which are well beyond the normal limits of injection devices and techniques, presenting many challenges for subcutaneous, subretinal, intramuscular, and other forms of drug delivery.

Related Links:
Altaviz


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Medical Monitor
SILENIO D
PACS Workstation
PaxeraView PRO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.